Location: Multi-centers throughout the US and Canada

Purpose: A phase IV study to compare the total number of relapses experienced by patients randomized to maintain treatment on high dose INF therapy compared to those who were transferred to Copaxone® (glatiramer acetate) in patients with relapsing multiple sclerosis.

Eligibility:
• Men and women ages 18 to 50
• Diagnosis of clinically definite MS with a relapsing disease course
• Must be on either Rebif® or Betaseron® for a minimum of 1 year prior to study entry
• Relapse history to meet the eligibility criteria of the study.

Procedures:
• Participants will receive injections of either INF or Copaxone for 3 years
• MRIs will be performed every 6 months for the duration of the study

Benefit: Primary outcome will be the analysis of the difference in relapse rate between the 2
groups of patients.

For Information: Please call 1-866-550-0614 or go to www.centerwatch.com or www.nationalmssociety.org

This entry was posted on Thursday, July 14th, 2005 at 10:00 am and is filed under All Articles, MS Study Enrollments. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.